Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Short Interest Update

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) saw a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 371,600 shares, a growth of 6.0% from the September 15th total of 350,500 shares. Approximately 2.9% of the company’s stock are sold short. Based on an average daily volume of 214,600 shares, the short-interest ratio is currently 1.7 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC increased its holdings in shares of Eagle Pharmaceuticals by 75.7% in the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 2,861 shares during the period. Creative Planning purchased a new position in Eagle Pharmaceuticals during the 3rd quarter worth $59,000. Mackenzie Financial Corp acquired a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter worth $60,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Eagle Pharmaceuticals during the second quarter worth about $65,000. Finally, Fidelis Capital Partners LLC acquired a new position in shares of Eagle Pharmaceuticals during the second quarter worth about $71,000. 85.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Eagle Pharmaceuticals in a research note on Saturday, October 12th. They issued a “hold” rating for the company.

Eagle Pharmaceuticals Price Performance

Shares of EGRX stock traded down $0.15 during trading hours on Thursday, hitting $0.65. The stock had a trading volume of 44,085 shares, compared to its average volume of 204,322. The stock’s 50 day moving average is $3.56 and its 200 day moving average is $4.28. The firm has a market capitalization of $8.44 million, a PE ratio of 0.78 and a beta of 0.51. Eagle Pharmaceuticals has a twelve month low of $0.10 and a twelve month high of $14.78.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.